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Abstract 
Lupus nephritis is one of the most serious complications of systemic lupus erythematosus 
(SLE). In the kidney, immune complexes and autoantibodies activate mesangial cells that 
secrete cytokines that can further amplify inflammatory processes. We present the case of a 
42-year-old woman with lupus nephritis accompanied by periods of exacerbation of SLE, with 
necrotic-like skin lesions, psoriatic arthritis without skin psoriasis, purpura of the lower limb, 
petechial rash, joint pain, fever, eyelid edema with bilateral conjunctival hyperemia and itch-
ing. The patient underwent a dialytic treatment of hemodiafiltration with endogenous reinfu-
sion. The technique uses the super-high-flux membrane Synclear 02 (SUPRA treatment) cou-
pled with an adsorbent cartridge that has affinity for many toxins and mediators. Fever and 
joint pain were immediately reduced after treatment and, subsequently, there was a notable 
reduction of the skin damage. Prednisone and immunosuppressive drugs were gradually 
reduced until complete suspension. High-performance liquid chromatography coupled with 
quadrupole time-of-flight mass spectrometer was performed for identification of proteins 
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captured by a resin bed during a dialysis session of the patient. This technique identified 
several biomarkers of kidney injuries, uremic toxins, fragments of immunoglobulins, antigens 
involved in antiphospholipid syndrome and a new marker (α-defensin) that correlated signif-
icantly with disease activity. The removal of these different proteins could possibly provide an 
explanation of the improvement in the patient’s symptoms and the normalization of her SLE. 
SUPRA coupled with an adsorption may be a promising new technique for the treatment of 
lupus nephritis. © 2015 S. Karger AG, Basel 
Introduction 
Lupus nephritis (LN) is one of the most severe manifestations of systemic lupus erythe-
matosus (SLE). The clinical course ranges from asymptomatic urinary occult blood to ne-
phrotic syndrome or acute kidney injury. LN is associated with considerable morbidity and 
mortality [1]. 
Cytokines play a key role in disease initiation and progression; in fact, in the kidney, 
immune complex deposition activates mesangial cells. Once activated by immune complexes 
and/or autoantibodies, renal resident cells secrete cytokines that may further amplify in-
flammatory processes [2]. 
Case Report 
A 42-year-old woman presented with LN due to SLE. She was first admitted to the Neph-
rology and Dialysis Department of San Benedetto del Tronto Hospital in 2003 due to the 
detection of urinary abnormalities and increased creatinine (up to 3 mg/dl). She had a pre-
sumptive diagnosis of psoriatic arthritis since 2002. An in-depth diagnostic and biopsy anal-
ysis led to the definitive diagnosis of SLE with LN [medical report of optical microscopy as-
cribable to LN (class II according to the WHO) with activities 7 and stage 0, medical report of 
electronic microscopy compatible with the diagnosis of LN (class III according to the WHO) 
and antiphospholipid syndrome (APS) with presence of lupus anticoagulant antibodies and 
anticardiolipin antibodies].  
Subsequently, the patient was subjected to treatment with induction immunosuppres-
sive therapy with cyclophosphamide and prednisone for periodic exacerbation of basic im-
munological disease when she presented with proteinuria, high levels of inflammatory 
markers and abnormal liver function. She also had periods of clinical stability (characterized 
by a general improvement with normalization of liver and kidney function and remission of 
proteinuria) with mycophenolate mofetil. 
These cycles continued until 2006, when she presented with hemolytic-uremic syn-
drome with severe hypertension (260/130 mm Hg), grand mal and oliguria. She was then 
started on hemodialysis due to the rapid deterioration of renal function which, despite a new 
cycle of induction therapy, produced end-stage renal disease and required chronic hemodi-
alysis treatment. 
During the initial hemodialysis period, she continued therapy with mycophenolic acid 
and prednisone. Symptoms and signs of systemic disease activity persisted and included 
arthralgia, asthenia, episodic fever, maculopapular rash, elevated erythrocyte sedimentation 
rate and leuko-thrombocytopenia. Although the patient underwent 1–4 plasma exchanges 
(PEX) per month, the combination of PEX with methylprednisolone bolus and IgG admin-
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istration achieved only limited improvements of arthralgia and cutaneous manifestations 
(necrotic-like skin lesions).  
During the last 2 years, the patient has been started on a new hemodiafiltration tech-
nique, hemodiafiltration with endogenous reinfusion dialysis treatment, which uses the su-
per-high-flux membrane Synclear 02 (SUPRA treatment) coupled to an adsorbent cartridge. 
Fever and joint pain were significantly reduced as early as in the first week of treatment. 
During the following few months, skin manifestations were significantly reduced and the 
patient reported an improved quality of life (QoL). After starting SUPRA (3 times weekly for 
4 h per session), the patient no longer needed any additional PEX treatment. Prednisone and 
immunosuppressors were gradually reduced and eventually discontinued since the im-
provement of symptoms suggested a trend towards systemic remission.  
After 6 months of prednisone and mycophenolic acid therapy suspension, there were no 
further events to be considered as an expression of SLE activity. The patient has reported an 
improvement in asthenia and has not experienced any further episodes of fever or arthral-
gia. She currently continues using the SUPRA technique. 
Laboratory analysis showed an improvement in leuko-thrombocytopenia; however, the 
patient still has a persistent elevation of the erythrocyte sedimentation rate, low levels of C3 
and C4 complement and a moderate increase in IgG and antinuclear antibody. 
The QoL of the patient was analyzed by the RAND 36-Item Health Survey before starting 
and 3 weeks after SUPRA treatment. The resulting scores illustrate how the SUPRA treat-
ment led to an improvement in QoL. In particular, physical functioning, energy/fatigue and 
pain scores increased from 20 to 90, 15 to 70 and 22.5 to 67.5, respectively. 
Although the timing between the beginning of SUPRA treatment and the complete re-
mission of SLE symptoms may suggest an association between the SUPRA therapy and clini-
cal improvement, we cannot exclude that there was a spontaneous remission of systemic 
disease, as known to occur sometimes in dialysis patients. This case, moreover, places fur-
ther emphasis on the role of inflammatory mediators in SLE symptom manifestations and 
the therapeutic potential of SUPRA treatment. 
Discussion 
LN increases the morbidity and mortality of patients with SLE. SLE patients commonly 
have increased levels of IL-6 and IL-10, which further increase in patients with active dis-
ease. 
Jacob and Stohl [3] have rated four cytokines [IL-6, tumor necrosis factor α (TNF-α), 
IFN-α and B-lymphocyte stimulator (BLyS)] as therapeutic targets in SLE. This study shows 
that the reduction of these proinflammatory cytokines has a beneficial effect on the course of 
the disease. To date, the potential of cytokines as therapeutic targets for lupus has been 
shown both by a BLyS inhibitor (belimumab, recently approved by the United States Food 
and Drug Administration as a treatment for SLE) and by ongoing trials on other cytokine 
inhibitors [4]. 
In particular, IL-6 is a multifunctional cytokine produced in response to inflammatory 
stimuli, including those mediated by IL-1 and TNF-α, with key roles in the regulation of the 
immune response to infections. IL-6 was indicated as a potent stimulator of the differentia-
tion and activation of lymphoid and myeloid cells and the production of acute-phase pro-
teins in the liver. IL-6 is also a key regulator of many other cellular processes, including 
erythropoiesis, neuronal cell differentiation and bone metabolism. There is an inverse corre-
lation between levels of IL-6 and hemoglobin levels in patients with SLE. 
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Hemodiafiltration with on-line endogenous reinfusion (HFR-SUPRA treatment) is a dia-
lytic method which combines the processes of diffusion, convection and adsorption. The 
performance of this system is linked to the optimal combination of the membrane permea-
bility and cartridge resin bed [5]. 
It has been demonstrated that the sorbent cartridge has a high affinity for several ure-
mic toxins and middle molecules, such as β2-microglobulin, homocysteine, angiogenin, lep-
tin, parathormone and some chemokines and cytokines. In contrast, the cartridge does not 
retain bicarbonate, amino acids and hydrosoluble vitamins. Other solutes, such as urea, cre-
atinine, uric acid, Na+, K+, Ca2+, phosphate and bicarbonate, which are not adsorbed by the 
cartridge, are cleared, by diffusion, in the second chamber of the filter [6–8]. 
In addition to cytokine removal information, high-performance liquid chromatography 
coupled with quadrupole time-of-flight mass spectrometer (HPLC-QTOF-MS) was used for 
the identification of proteins in the ultrafiltrate and the species captured by the resin bed 
(eluted proteins), obtained in a dialysis session of the patient (fig. 1; table 1). 
Several biomarker of LN kidney injuries were identified in HPLC-QTOF analysis of elut-
ed proteins, such as retinol-binding protein 4 (RBP4), neutrophil gelatinase-associated 
lipocalin (NGAL), zinc α-2 glycoprotein (ZA2G) and cystatin-C (CYTC). 
Moreover, additional uremic toxins such as serotransferrin (TRFE), α-1-acid glycopro-
tein (A1AG1), prostaglandin-H2 D-isomerase (PTGDS) and transthyretin (TTHY) were iden-
tified. All of these markers are considered, by Varghese et al. [9], as biomarkers for glomeru-
lar disease. Furthermore, Suzuki et al. [10] initiated the validation of TRFE, ceruloplasmin 
(CERU), A1AG1, PTGDS, albumin and albumin-related fragments as biomarkers for active 
pediatric LN. Clearly, we identified several fragments of immunoglobulins that are implicat-
ed in the etiopathogenesis of SLE.  
Another important protein in the pathophysiology of SLE is β-2-glycoprotein 1 (APOH), 
the principal autoantigen in APS. APS is associated with arterial and venous thrombosis, 
characterized by up to 30 different autoantibodies [11]. APOH, an abundant plasma phos-
pholipid-binding protein, binds to anionic zwitterionic phospholipids, involved in clotting, 
but its physiological function is not completely understood [12]. 
Last but not least, we found neutrophil defensin 1 (DEF1) among the identified proteins, 
a member of the α-defensin family. DEF1 – and DEF2 – has antibacterial, fungicide and anti-
viral activities. Both have antimicrobial activity against Gram-negative and Gram-posi- 
tive bacteria. Defensins are thought to kill microbes by permeabilizing their plasma mem-
brane [13]. 
In addition to exerting direct antimicrobial effects, defensins facilitate and amplify sub-
sequent innate and adaptive immune responses, such as activation and degranulation of 
mast cells, interleukin and TNF production and maturation of dendritic cells. 
Sthoeger et al. [14] have shown that the presence of high serum levels of α-defensin cor-
relates with higher rates of arthritis and renal and dermatological involvement and, in gen-
eral, the α-defensin levels correlate significantly with disease activity. Thus, when α-defensin 
levels decreased to the normal range, an improvement in lupus-related manifestations was 
observed. 
If compared with patients with low α-defensin levels, most SLE patients with high levels 
of DEF1 were treated with corticosteroids. Probably, the elimination of this protein from 
blood could explain the reduction in corticosteroid administration [14]. 
The results of this study demonstrate that styrenic resin retained several proteins im-
plicated in the LN pathogenesis. This means that SUPRA treatment is a dialysis method that 
reduces inflammatory status, uremic toxin level and could improve LN prognosis may- 
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be through the counterbalance of the immune-modulatory response and the reduction of  
the APS. 
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Table 1. Proteins identified in resin eluate and ultrafiltrate by HPLC-QTOF-MS analysis 
   
   
Eluted Ultrafiltrate before 5 min Ultrafiltrate after 235 min 
      
      
  PRE 0   
  – 
– 
Protein AMBP  
Ig γ-1 chain C region 
  
            E1      
– 
– 
TRFE  
Serum albumin 
    
            E2      
– 
– 
– 
– 
– 
– 
– 
– 
Serum albumin  
Vitamin D-binding protein  
α-1-Antitrypsin  
APOH 
Ig γ-1 chain C region  
α-2-HS-glycoprotein  
Ig γ-2 chain C region  
Monocyte differentiation antigen CD14 
    
            E3      
– 
– 
– 
– 
– 
– 
– 
Apolipoprotein A-IV  
ZA2G 
A1AG1 
A1AG2 
Complement factor H-related protein 1  
Leucine-rich α-2-glycoprotein 
Protein AMBP 
    
            E4      
– 
– 
– 
Insulin-like growth factor-binding protein 2  
Protein AMBP  
Ig γ-1 chain C region 
    
            E5   PRE 5   
– 
– 
– 
– 
Complement factor D  
Apolipoprotein A-I  
PTGDS 
Immunoglobulin λ-like polypeptide 5 
– 
– 
– 
– 
– 
Immunoglobulin λ-like polypeptide 5  
Complement factor D  
Apolipoprotein A-I  
PTGDS 
Ganglioside GM2 activator 
  
          E6  PRE 6 PRE fine 6 
– 
– 
– 
RBP4  
Tetranectin  
NGAL 
– 
– 
– 
RBP4  
NGAL 
Tetranectin 
– 
– 
– 
RBP4  
NGAL  
Tetranectin 
            E7  PRE 7   
– 
– 
TTHY  
Ribonuclease 4 
– TTHY   
            E8  PRE 8   
– 
– 
– 
– 
– 
Lysozyme C  
CYTC 
DEF1  
Angiogenin  
Guanylin 
– 
– 
– 
– 
– 
– 
– 
CYTC 
Lysozyme C  
Ig κ chain C region  
Ig λ-2 chain C regions  
DEF1  
Angiogenin  
Profilin-1 
  
            E9  PRE 9    
– 
– 
β-2-Microglobulin  
DEF1 
– 
– 
β-2-Microglobulin  
DEF1 
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Fig. 1. SDS-PAGE of proteins captured by resin bed (eluted proteins), ultrafiltrate before and after car-
tridge at the beginning (5 min) and at the end of treatment (235 min) and serum before and after dialysis. 
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